NACDS rolls out mobile Web app
ALEXANDRIA, Va. The National Association of Chain Drug Stores has introduced a mobile Web-based application in line with its upcoming 2010 Marketplace Conference.
The app, NACDS said, was created to enhance and improve attendees’ experience at the conference, which will be held this weekend in San Diego. The free download offers such detailed conference information as biographical information on speakers, an interactive map with routing information for booths, an exhibitor directory and a personalized show schedule.
“The new NACDS Marketplace Conference application is just one more tool in our communications toolbox to help us communicate effectively with the industry,” said Jim Whitman, NACDS SVP member programs and services. “The application provides a new and unique platform to leverage social media technology and create an even more vigorous conference experience that is consistent with our members’ priorities in creating effective tools for collaboration and innovation.”
The NACDS mobile app is compatible with most smartphone platforms, including Blackberry, Droid, iPhone, iPad and iPod Touch devices.
Teva launches generic Yaz
JERUSALEM Teva Pharmaceutical Industries has launched a generic oral contraceptive, the drug maker said Tuesday.
Gianvi is the generic version of Bayer’s Yaz tablets, which had total sales of nearly $782 million in the United States for 12 months ended Dec. 31. Teva has been awarded a 180-day period of marketing exclusivity for the contraceptive.
As previously announced, Teva has the right to launch an authorized generic version of the product, supplied by Bayer, in July 2011.
Consumer Reports survey: Antidepressant use on the rise
YONKERS, N.Y. A new Consumer Reports health survey found that nearly 80% of respondents seeking treatment for depression or anxiety were prescribed antidepressants.
Of the 1,500 subscribers surveyed, Consumer Reports found that 78% respondents use antidepressants to aid their mental health issues. CR also found that 58% had experienced anxiety, up from 41% in 2004 when CR last surveyed subscribers about these conditions. The survey sought to show how subscribers treat their mental health conditions and asked readers who took drugs for anxiety, depression or both within the past three years to rate them.
The survey also found that older, often less expensive antidepressants known as SSRIs (selective serotonin reuptake inhibitors) such as Lexapro, Celexa, Prozac and Zoloft work just as well, and with fewer side effects (51% of respondents said), than newer, more costly drugs known as SNRIs (serotonin and norepinephrine reuptake inhibitors) like Cymbalta and Effexor (49%). SSRIs and SNRIs address depression by altering the levels of certain brain chemicals, CR said.
CR also found, however, that talk therapy was effective in treating anxiety or depression in patients, it received high marks from CR’s survey participants–91% said therapy made things “a lot” or “somewhat” better. People who stuck with talk therapy for at least seven sessions had significantly better outcomes that those who went to six or fewer sessions. What’s more, they scored as high as people treated mostly with medication on an overall outcome scale.
“Pharmaceutical companies stand to profit most from convincing consumers that drugs are the only answer to depression and anxiety, and that newer, more expensive drugs are a better alternative to older drugs and their generic counterparts,” said Nancy Metcalf, senior program editor, Consumer Reports Health. “Our survey shows that a combination of therapy and medication works best, and that despite the intense marketing push consumers are subjected to, there is no evidence that newer drugs like Pristiq and Cymbalta work any better than older medications in their class.”
Click here to read the full report.